Loading
Endeavor Biomedicines
  • Home
  • About
    • Our Story
    • Leadership
    • Board of Directors
  • Science
    • Precision Medicine
    • Oncology
    • IPF
  • Patients
    • IPF
    • Oncology
  • Pipeline
    • ENV-101 (ONC)
    • ENV-101 (IPF)
  • Join Us
    • Mission
    • Culture
    • Open Positions
  • News
  • Contact
  • Back to Top
  • Menu Menu

Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program From Salk Institute, Sanford Burnham Prebys

January 19, 2022/in media, news
https://endeavorbiomedicines.com/wp-content/uploads/precision-oncology-logo-1.svg 52 273 Emily Hennes /wp-content/uploads/logo.png Emily Hennes2022-01-19 15:48:062022-01-31 17:59:11Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program From Salk Institute, Sanford Burnham Prebys

Endeavor BioMedicines raises $62 million to combat pulmonary disease

January 19, 2022/in media, news
https://endeavorbiomedicines.com/wp-content/uploads/techcrunch-logo-1.svg 52 364 Emily Hennes /wp-content/uploads/logo.png Emily Hennes2022-01-19 15:49:162022-01-19 15:49:16Endeavor BioMedicines raises $62 million to combat pulmonary disease

1st Patient Dosed in Trial of IPF Therapy Candidate Taladegib

January 19, 2022/in media, news
https://endeavorbiomedicines.com/wp-content/uploads/PF_News_logo-gray-01.svg 100 100 Emily Hennes /wp-content/uploads/logo.png Emily Hennes2022-01-19 15:47:182022-02-01 18:52:241st Patient Dosed in Trial of IPF Therapy Candidate Taladegib

Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly

January 19, 2022/in media, news
https://endeavorbiomedicines.com/wp-content/uploads/scrip-logo-1.svg 52 169 Emily Hennes /wp-content/uploads/logo.png Emily Hennes2022-01-19 15:50:002022-01-19 15:50:00Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly

Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease

January 21, 2022/in media, news

https://endeavorbiomedicines.com/wp-content/uploads/Stat_News_logo-gray.svg 100 100 Emily Hennes /wp-content/uploads/logo.png Emily Hennes2022-01-21 17:34:072022-01-21 17:47:16Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease

My newest puzzle, Endeavor BioMedicines, and the chance to reverse a devastating pulmonary disease

January 31, 2022/in media, news
https://endeavorbiomedicines.com/wp-content/uploads/linkedin-gray.svg 100 100 Emily Hennes /wp-content/uploads/logo.png Emily Hennes2022-01-31 18:09:392022-02-01 18:52:55My newest puzzle, Endeavor BioMedicines, and the chance to reverse a devastating pulmonary disease
  • Home
  • About
    • Our Story
    • Leadership
    • Board of Directors
  • Science
    • Precision Medicine
    • Oncology
    • IPF
  • Patients
    • IPF
    • Oncology
  • Pipeline
    • ENV-101 (ONC)
    • ENV-101 (IPF)
  • Join Us
    • Mission
    • Culture
    • Open Positions
  • News
  • Contact
  • Back to Top

© 2023 – Endeavor Biomedicines | Privacy Notice | Terms of Use

Scroll to top